Molecular Partners AG Q4 FY2023 earnings call

• 2023 was productive with progress on all programs. MPO533 tetra-specific T cell-engager in AML MDS had first patient dosed, ASH 2023 reported good safety and efficacy, and cohort 6 fully recruited. • Switch-DARPin platform nominated first target, working towards candidate. • Radio-DARPin platform achieved kidney retention reduction and increased tumor uptake, with breakthroughs in DLL3 program and collaborations with Orano Med and Novartis. • MPO317 advanced through Phase 1 with favorable safety profile and biological proof-of-concept. • Philippe Legenne discussed MPO533 trial details, Anne Goubier talked about Switch-DARPin for AML, Daniel Steiner discussed Radio-DARPin platform and internal targets.

Revenue in 2023 was CHF7 million, exclusively from the Novartis RadioLigand Therapies agreement. Operating expenses totaled CHF68 million, with R&D at CHF49 million and SG&A at CHF19 million. Cash balance was CHF187 million. Revenue in 2022 related to Novartis option exercise. Operating expenses for 2024 are guided to CHF70 million to CHF80 million, excluding partnership payments.

• Operating expenses for 2024 guided to CHF70 million to CHF80 million, excluding partnership payments. • Cash balance of CHF187 million carries well into 2026, allowing investment in pipeline and bringing drugs to patients.

Q: Richard Vosser asked about MPO533 dose expansion, safety, efficacy, and Phase 2 timing.

A: Patrick Amstutz said highest dose was calculated for 80% receptor occupancy, safety is benign, and update on efficacy and Phase 2 will come later.

Q: Michael Nedelcovych asked about MPO533 interim data expectations and Switch-DARPin platform.

A: Patrick Amstutz and Philippe Legenne discussed expected efficacy in relapsed/refractory settings and Switch-DARPin platform applicability.

Q: Kathleen Silverman asked about MPO533 data and biomarkers.

A: Patrick Amstutz said interim update on MRD and biomarkers will be shared.

Q: Joris Zimmermann asked about RDT platform internal targets and MPO317 update.

A: Patrick Amstutz said MPO317 trial is finalizing, data room opening, and Daniel Steiner discussed RDT platform internal targets and partnerships